Central perivenulitis: A common and potentially important finding in late posttransplant liver biopsies
Stefan G. Hübscher – 23 April 2008
Reply: Effect of prophylaxis on fungal infection and costs for high‐risk liver transplant recipients
Shirish Huprikar – 23 April 2008
Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors
Edie Y. Chan, Les C. Olson, James A. Kisthard, James D. Perkins, Ramasamy Bakthavatsalam, Jeffrey B. Halldorson, Jorge D. Reyes, Anne M. Larson, Adam E. Levy – 23 April 2008 – The use of donation after cardiac death (DCD) donor hepatic allografts is becoming more widespread; however, there have been published reports of increased graft failure from specific complications associated with this type of allograft. The complication of ischemic cholangiopathy (IC) has been reported to occur more frequently after the use of DCD hepatic allografts.
Metabolic liver disease in children
Keli Hansen, Simon Horslen – 23 April 2008 – The aim of this article is to provide essential information for hepatologists, who primarily care for adults, regarding liver‐based inborn errors of metabolism with particular reference to those that may be treatable with liver transplantation and to provide adequate references for more in‐depth study should one of these disease states be encountered. Liver Transpl 14:713–733, 2008. © 2008 AASLD.
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance
Scott Preiss, Margaret Littlejohn, Peter Angus, Alex Thompson, Paul Desmond, Sharon R. Lewin, Joe Sasadeusz, Gail Matthews, Gregory J. Dore, Tim Shaw, Vitini Sozzi, Lilly Yuen, George Lau, Anna Ayres, Chloe Thio, Anchalee Avihingsanon, Kiat Ruxrungtham, Stephen Locarnini, Peter A. Revill – 21 April 2008 – Defective hepatitis B virus DNA (dDNA) is reverse‐transcribed from spliced hepatitis B virus (HBV) pregenomic messenger RNA (pgRNA) and has been identified in patients with chronic HBV (CH‐B).
A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection
Clovis Palmer, Taline Hampartzoumian, Andrew Lloyd, Amany Zekry – 21 April 2008 – Adipose tissue releases pro‐inflammatory and anti‐inflammatory mediators, including adiponectin, which elicit a broad range of metabolic and immunological effects. The study aim was to determine in subjects infected with chronic hepatitis C virus (HCV) the effects of total adiponectin and its high‐molecular‐weight (HMW) and low‐molecular‐weight isoforms on HCV‐specific immune responses. Serum levels of total adiponectin and its isoforms were determined by immunoassay.
Reduced cardio‐respiratory fitness in obesity with and without nonalcoholic fatty liver disease
Melania Manco, Valerio Nobili – 18 April 2008
Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression
Hla‐Hla Thein, Qilong Yi, Gregory J. Dore, Murray D. Krahn – 18 April 2008 – Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage‐specific fibrosis progression rates and their determinants in these individuals. A systematic review of published prognostic studies was undertaken.
Long‐term follow‐up of antimitochondrial antibody–positive autoimmune hepatitis
Conor O'Brien, Supriya Joshi, Jordan J. Feld, Maha Guindi, Hans P. Dienes, E. Jenny Heathcote – 18 April 2008 – Antimitochondrial antibodies (AMAs) are the serological hallmark for primary biliary cirrhosis (PBC). When AMAs are detected in patients with chronic hepatitis, they negatively impact on the autoimmune hepatitis (AIH) scoring system. The purpose of this study was to determine if AMAs detected in the sera of patients with overt AIH have clinical or pathological significance. All patients with a clinicopathologic diagnosis of AIH from one center were reviewed.
Liver‐specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice
Fabian Geisler, Florian Nagl, Pawel K. Mazur, Marcel Lee, Ursula Zimber‐Strobl, Lothar J. Strobl, Freddy Radtke, Roland M. Schmid, Jens T. Siveke – 18 April 2008 – The Notch pathway is an evolutionary conserved, intercellular signaling pathway that plays an important role in cell fate specification and the embryonic development of many organs, including the liver. In humans, mutations in the Notch receptor ligand Jagged1 gene result in defective intrahepatic bile duct (IHBD) development in Alagille syndrome.